114sek
1,3 %
Date:2024-03-28Time:12:59:00Latest report:Q4-2023List:First NorthTicker:MODTX
Market Cap:41 msekEnterprise Value:22 msekNet Sales:- msekEarnings:-17,9 msekEmployees:0ISIN:SE0015987904

Ratios

10-year key figure history for Modus Therapeutics turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Modus Therapeutics with index and moving average MA50 and MA200.

Stockprice:1,14
MA50:1,67
MA200:1,98
Price/MA200:-42,5 %
RSI (14):26,8
Price/MA50:-31,8 %

Description

Modus is a clinical biotechnology company that, through the patented polysaccharide sevuparin, is developing a treatment for sepsis and septic shock (blood poisoning). Behind the Company's operations is over 20 years of research on the positive mechanisms of action of sevuparin. By ensuring that sevuparin can be prescribed in several times higher doses than comparable polysaccharides, the harmful processes in the body that occur during sepsis could be stopped and septic shock could be prevented.

Biotechnology